| Methods |
Allocation: randomised
Blinding: double blind first 6 mo. for auranofin & placebo only
Design: parallel study, 3 arms (auranofin, GSTM, placebo)
Sample size at entry 30: auranofin 10; placebo 10, GSTM 10.
Analysis: Completers 100% follow‐up (auranofin 10; placebo 10) |
| Participants |
Country: UK
Patients with active RA
Age: mean auranofin 57.8 y (SD 11.4)
Duration of disease: mean auranofin 8.6y (SD 8.1)
Females: 85%
RH: not reported
Concomitant use of steroids: none
Concomitant use of other DMARDs: none
Previous use of DMARDs: not reported |
| Interventions |
Auranofin 6 mg/day or matching placebo or open GSTM IM 50 mg/wk
Treatment duration: 6 mo. then reallocated as necessary |
| Outcomes |
Articular index (modified Landsbury)
Pain
ESR |
| Notes |
Quality score: 3
Allocation concealment: unclear
Data for six mo. abstracted from bar graphs
SDs imputed from weighted average of CV of other studies. ADRs reported at 12 mo. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
